Cambridge: AstraZeneca has announced that Imfinzi (durvalumab) has been recommended for approval in the European Union (EU) for the treatment of adult patients with resectable ...

EconoTimes is a global, independent publication that delivers comprehensive news, analysis, and insights on the economy, finance, and markets. Based in Korea, we offer a unique perspective on global ...

EconoTimes is a global, independent publication that delivers comprehensive news, analysis, and insights on the economy, finance, and markets. Based in Korea, we offer a unique perspective on global ...

What are the best stocks right now for investors in the cancer drug development space? Seeking Alpha analysts offer their ...

Detailed price information for Novo Nordisk A/S ADR (NVO-N) from The Globe and Mail including charting and trades.

A ceremony marking the start of construction on AstraZeneca's new small molecule drug factory is held in Wuxi, East China's Jiangsu province, on May 8. [Photo provided to chinadaily.com.cn] ...

AstraZeneca (LSE:AZN) received a positive recommendation from the European Medicines Agency for its cancer therapy Imfinzi, ...

AstraZeneca wins CHMP nod for Imfinzi combo in muscle-invasive bladder cancer, based on data from the phase III NIAGARA study ...

AstraZeneca (AZN) stock in focus as its antibody drug Imfinzi gains EU panel support for treating muscle-invasive bladder ...

EMA committee recommends approval of AstraZeneca’s Imfinzi to treat adult patients with resectable muscle-invasive bladder cancer: Cambridge, UK Tuesday, May 27, 2025, 15:00 Hrs ...

(Alliance News) - AstraZeneca PLC on Tuesday said its Imfinzi, or durvalumab, therapy has been recommended for approval in the EU for the treatment of muscle-invasive bladder cancer.

EU regulators have recommended AstraZeneca’s Imfinzi for approval in the treatment muscle-invasive bladder cancer (MIBC).